Department of Hematology, Xiangya Hemophilia Diagnosis and Treatment Center, Xiangya Hospital, Central South University, China.
Powder Metallurgy Institute of Central South University, China.
Mater Sci Eng C Mater Biol Appl. 2022 Apr;135:112659. doi: 10.1016/j.msec.2022.112659. Epub 2022 Jan 13.
Blood purification therapy is widely used in patients with renal insufficiency and severe infections, where membrane-associated thrombosis is a side effect. How to improve the hemocompatibility of dialysis membranes and reduce thrombosis is a focus of current research, in which platelets play a key role. However, few dialysis membranes that directly inhibit platelets have been developed to date. In this study, a polyethersulfone (PES) membrane was modified with ticagrelor, a platelet P2Y receptor inhibitor, and detailed characterization was performed. The ticagrelor modified PES membrane (TMPES) showed good hydrophilicity and anti-protein adsorption and significantly inhibited platelet adhesion, aggregation, and activation, which demonstrated good antithrombotic properties. In addition, the membrane had excellent red blood cell (RBC) compatibility, anticoagulant, and antiinflammatory effects, which demonstrated superior biosafety in cell and animal experiments. Therefore, the TMPES dialysis membrane could have potential in clinical applications.
血液净化疗法在肾功能不全和严重感染患者中广泛应用，但膜相关血栓形成是其副作用。如何提高透析膜的血液相容性并减少血栓形成是当前研究的重点，其中血小板起着关键作用。然而，迄今为止，直接抑制血小板的透析膜很少得到开发。在这项研究中，聚醚砜（PES）膜被血小板 P2Y 受体抑制剂替格瑞洛修饰，并对其进行了详细的表征。替格瑞洛修饰的 PES 膜（TMPES）表现出良好的亲水性和抗蛋白吸附性，并且能够显著抑制血小板黏附、聚集和激活，表现出良好的抗血栓形成特性。此外，该膜对红细胞（RBC）具有良好的相容性、抗凝和抗炎作用，在细胞和动物实验中表现出优异的生物安全性。因此，TMPES 透析膜在临床应用中具有潜在的应用前景。
